Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lb Pharmaceuticals (LBRX) Change in Accured Expenses (2024 - 2026)

Lb Pharmaceuticals' quarterly Change in Accured Expenses came in at $3.5 million in Q1 2026, up 219.7% year-on-year from $1.1 million in Q1 2025, and up 76.28% quarter-over-quarter from $2.0 million in Q4 2025.

Lb Pharmaceuticals has reported Change in Accured Expenses for 3 years, with the latest figure at $3.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Accured Expenses rose 219.7% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at -$390000.0 (changed N/A YoY), and the FY2025 full-year result was -$910000.0, down 118.14% from the prior year.
  • Change in Accured Expenses for Q1 2026 stood at $3.5 million, up from $2.0 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $3.5 million in Q1 2026, with the low at -$2.9 million in Q4 2024.
  • Average Change in Accured Expenses over 3 years is -$97500.0, with a median of -$464500.0 recorded in 2025.
  • Year-over-year, Change in Accured Expenses jumped 167.18% in 2025 and surged 219.7% in 2026.
  • Tracing LBRX's Change in Accured Expenses over 3 years: stood at -$2.9 million in 2024, then surged by 167.18% to $2.0 million in 2025, then surged by 76.28% to $3.5 million in 2026.
  • The last three Change in Accured Expenses figures came in at $3.5 million (Q1 2026), $2.0 million (Q4 2025), and -$2.9 million (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 931,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 70.50 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 107.70 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -176.03 Mn
10 Lb Pharmaceuticals 789.92 Mn 789.92 Mn - 3.46 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 3.46 Mn
Mar 31, 2026 3.46 Mn
Dec 31, 2025 1.97 Mn
Dec 31, 2025 1.97 Mn
Mar 31, 2025 -2.89 Mn
Mar 31, 2025 -2.89 Mn
Dec 31, 2024 -2.93 Mn
Dec 31, 2024 -2.93 Mn